Phase I, Open-Label Study of the Safety and Dosimetry of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in Adult Patients With Advanced Fibroblast Activation Protein (FAP)-Positive Solid Tumors
Latest Information Update: 19 Dec 2023
At a glance
- Drugs 177 Lu LNC 1004 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Yantai LNC Biotechnology
- 05 Dec 2023 Status changed from not yet recruiting to recruiting.
- 18 Apr 2023 Planned initiation date changed from 10 Mar 2023 to 10 May 2023.
- 17 Feb 2023 New trial record